Evercore ISI Initiates Cigna Coverage with 'In Line' Rating and $290 Target

Evercore ISI has initiated coverage on Cigna Group (NYSE: CI), assigning an “In Line” rating with a price target of $290. This marks a key analyst update on Cigna in over a month. The rating and target were published on September 9, 2026, via Investing.com, signaling cautious optimism regarding the company’s outlook under current market conditions. The report identifies risks in transitions within Cigna’s pharmacy benefit management (PBM) operations, factors that Evercore views as critical in its evaluation.

This initiation of coverage follows several analyst actions earlier in the year, including a downgrade by Jefferies to “Hold” in early August and a revised price target by Guggenheim at the end of July. However, this new rating from Evercore ISI stands out as the most recent publicly available analyst opinion as of mid‑September. No explicit expectations have been detailed for Cigna’s stock performance, but the report emphasizes the evolving challenges the company faces amid PBM shifts.

When contextualizing Cigna’s recent performance, it’s important to note that no major earnings or regulatory announcements occurred within the past week that would clearly affect the stock. The most recent material developments include the company’s strong second‑quarter 2026 results on July 30, in which Cigna raised its full‑year adjusted profit outlook and delivered better‑than‑expected adjusted EPS and revenue. These results underpinned positive sentiment, but as of the latest week, investor attention has shifted toward analyst assessments like Evercore ISI’s, rather than fresh company developments.

Reliable data confirms that as of September 25, 2026, Cigna’s stock closed at $272.22, reflecting a 2.53% gain for the day, based on MarketBeat’s summary of Yahoo Finance figures. Extended hours trading added a modest further increase to $272.39. These figures align with reported daily moves on the Investing.com platform. While the Evercore ISI initiation did not immediately trigger a dramatic stock reaction, it contributes to the evolving narrative investors are tracking amid sector uncertainties.

What to Watch Next
Investors will likely monitor upcoming events such as Cigna’s scheduled Investor Day on September 30. That presentation may shed further light on the company’s strategic roadmap—particularly around PBM business dynamics—and offer fresh guidance on future performance. Analyst revisits or updates following that event could significantly influence sentiment in the short term.

In summary, the Evercore ISI initiation with a mid‑$290s price target presents a calibrated outlook on Cigna at a time when recent earning strength is being balanced against execution risks. As no direct causal evidence links this coverage initiation to a specific stock move, investors should treat it as one of several inputs shaping market expectations heading into late September.